Compass Therapeutics (CMPX) EBIT (2018 - 2026)

Compass Therapeutics has disclosed EBIT across 9 years of filings, most recently posting -$20.3 million for Q1 2026.

• EBIT for Q1 2026 came in at -$20.3 million, down 12.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$75.2 million (down 21.59% YoY), and the FY2025 annual result was -$72.8 million, down 28.63% from the prior year.
• EBIT came in at -$20.3 million for Q1 2026 at Compass Therapeutics, down from -$18.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$7.2 million in Q1 2022 to a low of -$21.1 million in Q2 2025.
• The 5-year median for EBIT is -$13.3 million (2023), against an average of -$14.2 million.
• Across the five-year window, EBIT tumbled 115.2% in 2022 and advanced 5.33% in 2023, its largest moves.
• Compass Therapeutics' EBIT stood at -$12.9 million in 2022, then retreated by 19.44% to -$15.4 million in 2023, then declined by 7.67% to -$16.6 million in 2024, then declined by 8.54% to -$18.0 million in 2025, then declined by 12.83% to -$20.3 million in 2026.
• The last three EBIT figures came in at -$20.3 million (Q1 2026), -$18.0 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.